drugset / Trial / NCT01461460

A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

NCT01461460

Phase 1 Completed 48 enrolled Merck & Co., Inc.
RandomizedCrossoverDouble-blindOther

Summary

The purpose of this study is to assess the effects of oral TR-701 free acid (FA) versus placebo on QTcF.

Timeline

Start
2011-11-28
Primary completion
2011-12-23
Completion
2011-12-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 400 mg
Subject Tedizolid Small molecule 200 mg Oral
Subject Tedizolid Small molecule 1200 mg Oral

Indications

No indication recorded.